Alector reports second quarter 2020 financial results and provides corporate update

Alector reports second quarter 2020 financial results and provides corporate update.alector inc - al002, al003 and al014 programs for treatment of alzheimer's disease and al101 neurology program continue to progress.alector inc - promising preliminary data from al001 phase 1b and phase 2 open-label studies.alector inc - plans to initiate phase 1 development for al014 in first half of 2021.alector inc - qtrly loss per share $0.58.alector inc - collaboration revenue for quarter was $3.2 million versus $6.9 million.
ALEC Ratings Summary
ALEC Quant Ranking